GSK•benzinga•
GSK's Phase 3 Trials SWIFT-1 and SWIFT-2 Of Depemokimab Versus Placebo In Severe Asthma Patients With Type 2 Inflammation Met Primary Endpoints Of Reduction In Annualized Rate Of Clinically Significant Exacerbations (Asthma Attacks) Over 52 Weeks
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2024 by benzinga